Skip to main content

Table 3 Comparison between group A and group B according to mRECIST at follow-up

From: Transarterial chemoembolisation in patients with hepatocellular carcinoma: low-dose doxorubicin reduces post-embolisation syndrome without affecting survival—prospective interventional study

mRECIST Group A (n = 15) Group B (n = 13) Test of Sig. p value
At 1 month
 CR 2 (13.3%) 4 (30.8%) χ2 = 1.512 0.640 (MC)
 PR 11 (73.3%) 7 (53.8%)
 SD 2 (13.3%) 2 (15.4%)
 PD 0 (0%) 0 (0%)
At 3 months
 CR 3 (20%) 5 (38.5%) χ2 = 4.775 0.250 (MC)
 PR 6 (40%) 6 (46.2%)
 SD 0 (0%) 1 (7.7%)
 PD 5 (33.3%) 1 (7.7%)
 Lost at follow-up 1 (6.7%) 0 (0%)
At 6 months
 CR 4 (26.7%) 7 (53.8%) χ2 = 3.129 0.325 (MC)
 PR 1 (6.7%) 0 (0%)
 SD 1 (6.7%) 0 (0%)
 PD 0 (0%) 0 (0%)
 Lost at follow-up 9 (60.0%) 6 (46.2%)
Overall survival
 < 6 months 3 (20%) 1 (7.7%) χ2 = 2.276 0.391 (MC)
 6–12 months 7 (46.7%) 4 (30.8%)
 > 12 months 5 (33.3%) 8 (61.5%)
 Mean ± standard deviation 14.3 ± 10.6 22 ± 12.7 U = 61.0 0.098
 Median (minimum–maximum) 10 (3–33) 23 (3–42)
  1. CR Complete response, MC Monte Carlo, mRECIST Modified Response Evaluation Criteria in Solid Tumors, PD Progressive disease, PR Partial response, SD Stable disease, U Mann–Whitney U test
\